Ahead of FDA adcomm, Pfizer, Moderna say COVID jab efficacy dips

Pfizer and Moderna have both reported data that they say backs up the need for booster shots of their COVID-19 vaccines ahead of an FDA advisory committee meeting tomorrow, although the regulator seems less convinced.

Documents published ahead of the panel by the FDA reviewers suggest that there is some evidence from observational studies that protection may be starting to fall away, but overall the available data suggests that “currently US-licensed or authorised COVID-19 vaccines still afford protection against severe…disease and death.”